Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $93.9 million.

  • Caribou Biosciences' Non-Current Assets fell 63.07% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year decrease of 63.07%. This contributed to the annual value of $93.9 million for FY2024, which is 0.61% up from last year.
  • Per Caribou Biosciences' latest filing, its Non-Current Assets stood at $93.9 million for FY2024, which was up 0.61% from $93.4 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' Non-Current Assets ranged from a high of $113.5 million in FY2022 and a low of $11.7 million during FY2020.
  • Over the past 3 years, Caribou Biosciences' median Non-Current Assets value was $93.9 million (recorded in 2024), while the average stood at $100.3 million.
  • Per our database at Business Quant, Caribou Biosciences' Non-Current Assets skyrocketed by 335.81% in 2021 and then declined by 17.75% in 2023.
  • Caribou Biosciences' Non-Current Assets (Yearly) stood at $11.7 million in 2020, then spiked by 335.81% to $51.2 million in 2021, then soared by 121.87% to $113.5 million in 2022, then declined by 17.75% to $93.4 million in 2023, then rose by 0.61% to $93.9 million in 2024.